Labiotech.eu’s Post

🚀 Major Funding Boost for Neurodegenerative Disease Research! 🧠 Forbion-backed Vectory Therapeutics has successfully raised $138 million to advance research into ALS and other neurodegenerative diseases. This significant funding will accelerate the development of innovative therapies, bringing hope to patients and families affected by these challenging conditions. Key Points: Funding Amount: $138 million Focus Areas: Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases Backed By: Forbion, a leading life sciences venture capital firm Impact: This funding will enable Vectory Therapeutics to accelerate the development of groundbreaking treatments and potentially transform the landscape of neurodegenerative disease research. Read more about this exciting development here: https://lnkd.in/gTuTZraD #Biotech #ALSResearch #NeurodegenerativeDiseases #Funding #HealthcareInnovation #VectoryTherapeutics #Forbion #MedicalResearch

Catch the biotech pulse: weekly roundup of sizzling funding updates 💰🔬 🇺🇸 Aiolos Bio | $245 million series A | antibody-based therapy | phase 1 in severe asthma 🇫🇷 Abivax | $235.8 million IPO | immune-related therapies | phase 3 in moderately to severely active ulcerative colitis 🇺🇸 Harpoon Therapeutics | up to $150 million PIPE | immuno-oncology | phase 1 in small cell lung cancer, neuroendocrine prostate cancer and other neuroendocrine tumors 🇺🇸 Rampart Bioscience | $85 million series A | gene therapies | developing treatment for an inherited metabolic disorder 🇨🇳🇺🇸 Angitia Biopharmaceuticals | $46 million series B extension financing | musculoskeletal disease therapeutics | phase 3 in bone-related disease 🇳🇴 Nykode Therapeutics | NOK 505 million ($45.18 million) PIPE | vaccine platform | phase 2 in HPV16-positive cervical cancer 🇺🇸 Actym Therapeutics, Inc. | $25.5 million series A | immuno-oncology | IND-enabling in solid tumors 🇸🇬 Gero | $6 million series A | longevity treatments | IND-enabling in age-related diseases #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

🚀 Exciting News for Biotech Enthusiasts! 🚀 Hey LinkedIn family! 👋 Thrilled to share insights on a recent Nasdaq article by the insightful Ari Zoldan, highlighting six clinical-stage biotech stocks with groundbreaking treatments. 💡 In the ever-evolving biotech landscape, it's crucial to spot potential winners, and Ari has done an exceptional job curating a list of small- and micro-cap gems with promising science and focus areas. 🧬✨ Here's a sneak peek: 1️⃣ Coya Therapeutics, Inc. (COYA): Tackling neurodegenerative, autoimmune, and metabolic diseases with Tregs. Exciting developments in #Alzheimer's and #ALS treatments! 2️⃣ Arvinas (ARVN): Pioneering targeted protein degradation with PROTAC. Keep an eye on their advancements in breast cancer, prostate cancer, and neurodegenerative diseases. 3️⃣ Cormedix Inc. (CRMD): Combatting catheter-related bloodstream infections with innovative solutions. Impressive 71% reduction in CRBSI risk in Phase 3 trials! 4️⃣ Ocuphire Pharma (OCUP): Focusing on retinal and refractive eye disorders. APX3330, their lead candidate for diabetic retinopathy, is making waves! 5️⃣ Rocket Pharmaceuticals (RCKT): Groundbreaking genetic therapies addressing rare illnesses. LV RP-L201 for leukocyte adhesion deficiency in FDA review - results expected March 31, 2024! 6️⃣ Ventyx Biosciences (VTYX): Innovating oral therapies for autoimmune and inflammatory diseases. VTX958, their lead candidate for psoriasis, is moving beyond Phase 2 trials! 🚨 Investing Considerations: Ari wisely cautions about the volatility in the biotech sector. As always, diligence is key! 🔍 🔗 Read the full article by Ari Zoldan: https://lnkd.in/gkgCiGTT 💬 Engage with this post, share your thoughts on these biotech disruptors, and let's foster a community of knowledge exchange! #Biotech #Innovation #Investing #AriZoldan #KnowledgeSharing

FluoSphera is a patent-protected technology platform developing a unique set of disruptive technologies mimicking the clinical response to drugs under systemic conditions to accurately predict drug safety and efficacy. Such high-throughput systemic assays reliably identify the most promising lead compounds early during drug discovery to decrease drug development failure in the clinic, thus increasing the chance for the patients to get access to the best therapeutics while reducing animal experimentation. Meet FluoSphera @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

Biotech startup Mirador Therapeutics has launched with a whopping $400 million in funding to revolutionize precision medicine for “immune-mediated inflammatory and fibrotic diseases.” While the company has not yet revealed which indications it is targeting, there are many chronic conditions that could potentially fall under such a scope, including rheumatoid arthritis, connective tissue disorders, and even neurological diseases such as multiple sclerosis. Mirador aims to address the treatment gap in immune-mediated diseases by tailoring treatments to individual genetic profiles, a strategy that has dramatically changed approaches in oncology. At the heart of the company’s strategy is its “precision development engine,” Mirador360, which harnesses recent advancements in human genetics and data science. The platform is designed to sift through vast amounts of patient data to uncover genetic associations to immune-mediated diseases, identify therapeutic targets, and explore potential combination therapies. Key to Mirador’s approach is its emphasis on genetic profiling. By pinpointing specific genetic targets, the company hopes to not only develop more effective treatments but also advance diagnostics and refine patient stratification for clinical trials.

With #JPM2024 behind us, #biotech fundraising seems to be returning to a more regular pace. ✅ Here's what our tracker found this week: 🇺🇸 Dyne Therapeutics | $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1 🇺🇸 Praxis Precision Medicines, Inc. | $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy | Read more 🇺🇸 Myrobalan Therapeutics | $24 million series A | CNS disease therapies | IND-enabling in multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis 🇩🇪 DISCO Pharmaceuticals GmbH | EUR 20 million ($21.75 million) seed | drug discovery | map of small cell lung cancer surfaceome completed 🇨🇭 STALICLA | $17.4 million series B | neurodevelopmental disorder-specific precision medicine platform | phase 1b in autism spectrum disorder 🇫🇮 DelSiTech Ltd | €10 million ($10.88 million) | drug delivery | clinical in chronic hepatitis B 🇺🇸 Cyrano Therapeutics | $9 million series B | phase 2 in post-viral smell loss 🇨🇦 XORTX Therapeutics Inc. | $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease 📌 Subscribe to Labiotech.eu to receive all our biotech updates.

🚀 Exciting News! Bastion Therapeutics Secures $840K in Launch Financing 🚀   🏰 We are thrilled to announce a major milestone for Bastion Therapeutics! We've secured $840,000 in launch financing to revolutionise the treatment of #InflammatoryDisorders and #AutoimmuneDiseases with our cutting-edge #Treg cell therapies.   💪 #Tregs play a pivotal role in a healthy immune system, expertly keeping #inflammation in check. In patients suffering from chronic inflammatory and autoimmune conditions, Tregs fail to control the relentless inflammation. 🛡️🔥Our #BastionVanguard is on a quest to not only restore but supercharge the function of Tregs with our GRIT™ Platform Technology, zeroing in on those sites of tissue inflammation.   🤝 This incredible funding round was led by NG Bio, a specialist investor in immunology and inflammatory diseases, along with Pioneer Group, Wren Capital LLP, and Deep Science Ventures.   🔬 We've already generated promising preclinical data, validating our Treg engineering technology. With this financing, we'll build our research capabilities, advance product development, and establish our laboratory at Scale Space.   🙌 Together with NG Bio, Pioneer Group, Wren Capital LLP, Deep Science Ventures, and our brilliant angel investors😇, we're on a mission to provide curative treatments for patients battling inflammatory disorders.   Visit our website to read the full press release 👇 https://lnkd.in/eQEg__xH   #Tregs #BastionTherapeutics #CellTherapy

Odimma Therapeutics is a startup (creation 2017) from Strasbourg developing a proprietary personalized and powerful immunotherapy platform based on the disruptive technology of Synthetic DNA and advanced algorithms. Odimma Therapeutics aims to treat patients suffering form hard to treat cancer in a shortened timeframe (8 weeks) .We have strong POC and secured GMP supply chain. Meet Odimma Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/eQkiWD2h #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW